The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•11 February 2026•

1 min read

FDA Expands Keytruda Use for Ovarian Cancer, Boosting Merck Prospects

Stylized metallic devices with 'Lilly' and 'SCYNEXIS PHARMACEUTICALS' logos, surrounded by scientific equipment, molecular structures, and data charts on a golden background.

The U.S. Food and Drug Administration (FDA) has granted expanded approval for Merck's blockbuster cancer drug, Keytruda, for use in previously treated patients with specific types of ovarian cancer. This significant approval is based on compelling data from the Phase 3 KEYNOTE-B96 trial, which demonstrated a statistically significant improvement in progression-free and overall survival. Keytruda continues to be a major revenue driver for Merck, having shown substantial sales growth in the fourth quarter of 2025. This expanded indication is anticipated to further solidify Merck's market position and contribute positively to its future sales trajectory. The move underscores growing confidence in the drug's efficacy and its potential to improve patient outcomes.